What's new

EMEA-002021-PIP01-16-M01

EMEA-002021-PIP01-16-M01

Jun 24, 2025 - 13:50
 0
EMEA-002021-PIP01-16-M01
EMEA-002021-PIP01-16-M01
Read More

Tags:

Previous Article

Opinion/decision on a Paediatric investigation plan (PIP): Zejula, niraparib (to...

Next Article

Human medicines European public assessment report (EPAR): Korjuny, catumaxomab, ...

Related Posts

Opinion/decision on a Paediatric investigation plan (PIP): Piqray, Alpelisib, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Congenital, familial and genetic disorders, PIP number: P/0090/2024

Opinion/decision on a Paediatric investigation plan (PI...

Jun 6, 2025  0

Human medicines European public assessment report (EPAR): Neparvis, sacubitril,valsartan, Date of authorisation: 26/05/2016, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR...

Jun 23, 2025  0

EMA roundtable with stakeholders on the 20th anniversary of the SME Regulation, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 17 October 2025, 09:30 (CEST) to 17 October 2025, 13:50 (CEST)

EMA roundtable with stakeholders on the 20th anniversar...

Jun 4, 2025  0